AlexanderBOlawaiyeMD
Obstetrics & Gynecology • Pittsburgh, PAGynecologic Oncology
Associate Professor, Ob/Gyn & Reproductive Science, University of Pittsburgh School of Medicine
Dr. Olawaiye is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Halket St
# Magee-Wo
Pittsburgh, PA 15213Phone+1 412-641-6665Fax+1 412-641-5417
Education & Training
Massachusetts General HospitalFellowship, Gynecologic Oncology, 2005 - 2008
University at BuffaloResidency, Obstetrics and Gynecology, 2001 - 2005
University of IbadanClass of 1991
Certifications & Licensure
PA State Medical License 2008 - 2024
MA State Medical License 2005 - 2016- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer Start of enrollment: 2008 Dec 01
- Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Start of enrollment: 2010 Sep 01
- Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2014 Jul 21
Publications & Presentations
PubMed
- 353 citationsNeoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guid...Alexi A. Wright, Kari Bohlke, Deborah K. Armstrong, Michael A. Bookman, William A. Cliby
Gynecologic Oncology. 2016-10-01 - 189 citationsLeptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2).R.R. Gonzalez, Salandre Cherfils, Maria Escobar, Jin H. Yoo, Cecilia Carino
The Journal of Biological Chemistry. 2006-09-08 - 8 citationsp53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.Martin Köbel, Eun-Young Kang, Ashley Weir, Peter F Rambau, Cheng-Han Lee
The Journal of Pathology. Clinical Research. 2023-05-01
Journal Articles
- Survival Advantage Associated with Multimodal Therapy in Women with Node‐Positive (Stage‐IIIC) Uterine Papillary Serous Carcinoma: A National Cancer Database StudyJ F Lin, K Muniz, P Gehrig, R P Edwards, A B Olawaiye, S Beriwal, P Sukumvanich, J L Kelley, BJOG: An International Journal of Obstetrics & Gynaecology
Press Mentions
Cervical Cancer in Women 65+ Often Deadly: So Why Not Screen?January 19th, 2023- Cervical Cancer in Women 65+ Often Deadly: So Why Not Screen?January 19th, 2023
- Health Disparities Q&A with Madeleine Courtney-Brooks, MD, MPHApril 11th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
